Subsequently, Perl et al. published the results of a post-hoc analysis of the phase III ADMIRAL study regarding the survival of patients with FLT3 R/R AML who received post-HSCT gilteritinib as maintenance. Here, FLT3 is linked to acute myeloid leukemia.